导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.71% | 2869/4766 |
| 近一周 | -1.16% | 1740/5456 |
| 近一月 | -1.84% | 1340/5412 |
| 近一季 | -4.98% | 1923/5222 |
| 近半年 | -3.54% | 2500/4911 |
| 近一年 | -0.04% | 2775/4391 |
| 近两年 | 32.45% | 2188/2953 |
| 近三年 | 20.90% | 1452/2252 |
| 成立以来 | 56.73% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.44% 1805/4961 |
6.91% 2781/5312 |
- - |
- - |
| 2025 | 11.37% 2750/4813 |
0.53% 1824/3635 |
2.33% 1644/4076 |
6.25% 3540/4524 |
1.90% 1168/4813 |
| 2024 | 14.90% 987/3463 |
2.45% 776/2808 |
-1.02% 898/3014 |
14.68% 1928/3129 |
-1.19% 1621/3463 |
| 2023 | -2.61% 595/2656 |
4.93% 854/2280 |
-1.82% 530/2385 |
-1.27% 502/2515 |
-4.25% 930/2655 |
| 2022 | -12.79% 299/2207 |
-9.81% 352/1919 |
3.41% 1157/2016 |
-10.02% 335/2113 |
3.92% 617/2208 |
| 2021 | -3.00% 882/1822 |
-1.10% 432/1255 |
1.93% 1029/1330 |
-8.17% 1112/1466 |
4.77% 314/1822 |
| 2020 | 30.44% 522/1250 |
-7.55% 551/1028 |
13.83% 589/1067 |
10.30% 563/1164 |
12.36% 473/1184 |
| 2019 | - - |
- - |
1.18% 137/788 |
1.79% 357/850 |
9.27% 239/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国联央视财经50ETF联接C VS. 长安沪深300非周期A(740101) |